Evidence map›Paper›PMID 40578465›Full record

ArticleThe American journal of medicine2025

Impact of Atherosclerotic Conditions and Cardiovascular Medications on Abdominal Aortic Aneurysm Growth.

Fahad Alkhalfan, Essa Hariri, Anu Aggarwal, Robert Burton, Bhairavi Rajasekar, Alliefair Scalise, Pulkit Chaudhury, Natalia Fendrikova Mahlay, A Phillip Owens, Scott J Cameron

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The American journal of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Fahad AlkhalfanSection of Vascular Medicine, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute of Case Western Reserve University, Cleveland, OH, USA.
Essa HaririDivision of Cardiology, Johns Hopkins Medicine, Baltimore, MD, USA.
Anu AggarwalDepartment of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute of Case Western Reserve University, Cleveland, OH, USA.
Robert BurtonDepartment of Internal Medicine, Cleveland Clinic, Cleveland, OH, USA.
Bhairavi RajasekarSection of Vascular Medicine, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Alliefair ScaliseSection of Vascular Medicine, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Pulkit ChaudhurySection of Vascular Medicine, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
Natalia Fendrikova MahlaySection of Vascular Medicine, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA.
A Phillip OwensDepartment of Internal Medicine, Division of Cardiovascular Health and Disease, University of Cincinnati, OH, USA.
Scott J CameronSection of Vascular Medicine, Department of Cardiovascular Medicine, Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Cleveland, OH, USA; Department of Cardiovascular and Metabolic Sciences, Cleveland Clinic Lerner Research Institute of Case Western Reserve University, Cleveland, OH, USA; Department of Hematology, Taussig Cancer Institute, Cleveland Clinic Foundation, Cleveland, OH, USA. Electronic address: cameros3@ccf.org.

Funding

Role of the Gut Microbiota in Abdominal Aortic AneurysmR01HL147171 · NHLBI · UNIVERSITY OF CINCINNATI · PI OWENS III, ALBERT PHILLIP · 2020 to 2023
$2.5M
Platelets as Biosensors and Mediators of Aortic Aneurysm GrowthR01HL158801 · NHLBI · CLEVELAND CLINIC LERNER COM-CWRU · PI CAMERON, SCOTT JAMES · 2021 to 2025
$2.5M
NHLBI NIH HHS R01 HL147171NHLBI NIH HHS R01 HL158801
6 · The paper itself

Abstract

backgroundWhile risk factors for atherosclerotic diseases and abdominal aortic aneurysms overlap, some risk factors, like diabetes, may slow aneurysm growth. The impact of atherosclerosis and its treatment on aneurysm growth is unknown. We aimed to investigate whether atherosclerotic conditions and cardiovascular medications are associated with faster aneurysm growth.

methodsAnnualized abdominal aortic aneurysm growth rates were assessed over 10 years. The presence of coronary artery disease, peripheral artery disease, renal artery stenosis, and internal carotid artery stenosis was ascertained. Multivariable logistic regression models assessed the association between atherosclerotic conditions and fast aneurysm growth (≥0.5 cm/year). We further stratified by medication use, including aspirin.

resultsCoronary artery disease, carotid artery stenosis, and renal artery stenosis were associated with reduced odds of fast aortic aneurysm growth, likely due to medications for treating these conditions. Aspirin was the only medication to show slower aneurysm growth regardless of disease co-morbidity. Patients with peripheral artery disease not managed by medications had faster aneurysm growth than those without peripheral artery disease. The addition of a Statin mediction was associated with a further reduction in fast aneurysm growth in patients with peripheral artery disease already taking aspirin.

conclusionAtherosclerosis in vascular beds outside of the aorta was associated with a lower risk of fast aneurysm growth. Peripheral artery disease without pharmacological therapy had higher rates of fast aneurysm growth. Aspirin showed decreased aneurysm growth regardless of the co-incident vascular disease in patients with abdominal aortic aneurysms, highlighting the importance of appropriate pharmacological therapy.

Indexed as

Aortic Aneurysm, AbdominalAtherosclerosisCardiovascular AgentsCoronary Artery DiseaseAgedAspirinCarotid StenosisFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedPeripheral Arterial DiseaseRenal Artery ObstructionRisk FactorsAspirinCardiovascular AgentsHydroxymethylglutaryl-CoA Reductase InhibitorsAbdominal aortic aneurysmsAtherosclerosis diabetesCarotid artery diseasePeripheral artery disease

Identifiers

PMID40578465
PMCPMC12377166

What Socratic holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.